NKTR supply chain intelligence for Nektar Therapeutics: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TAK | Takeda Pharmaceutical Company Limited | 95% | Reciprocal relationship from TAK graph: or (recombinant)), a treatment for hemophilia A (congenital factor VIII deficiency) for control and prevention of bleeding episodes, for perioperative manageme… |
| GANNET-BIOCHEM | GANNET-BIOCHEM | 92% | we are dependent on Gannet BioChem for the supply of PEG reagents |
| JEFFERIES-LLC | JEFFERIES-LLC | 92% | On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (coll… |
| PIPER-SANDLER-CO | PIPER-SANDLER-CO | 92% | On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (coll… |
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 92% | On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (coll… |
| FLG | Flagstar Bank, National Association | 90% | Reciprocal relationship from FLG graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from FLG graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from FLG grap… |
| FLG | Flagstar Bank, National Association | 90% | In connection with Ms. Rubinstein's becoming the Company's interim Chief Financial Officer, the Company entered into an amendment (the "Amendment") to its consulting agreement with FLG for the provis… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from CTMX g… |
| IOBTQ | IOBTQ | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| IOBTQ | IOBTQ | 72% | Reciprocal relationship from IOBTQ graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from IOBTQ graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from IOBT… |
| LLY | Eli Lilly and Company | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual pro… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from NVO graph: Reciprocal relationship from NKTR graph: . We currently do not intend to sell … |
| NVO | Novo Nordisk A/S | 72% | . We currently do not intend to sell these securities prior to maturity and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis… |
| ODTX | ODTX | 72% | to target the TNFR2 pathway and include Dualyx, TRexBio, Inc., Odyssey Therapeutics, Inc., and Pfizer, Inc. Research and Development Our total research and development expenditures can be disaggregat… |
| ODTX | ODTX | 72% | Reciprocal relationship from ODTX graph: Reciprocal relationship from NKTR graph: to target the TNFR2 pathway and include Dualyx, TRexBio, Inc., Odyssey Therapeutics, Inc., and Pfizer, Inc. Research … |
| SGMO | Sangamo Therapeutics, Inc. | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual pr… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from NKTR graph: em 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses rela… |
| SNYNF | Sanofi | 72% | em 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, i… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | 72% | Reciprocal relationship from BHC graph: Reciprocal relationship from NKTR graph: the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all tim… |
| BHC | Bausch Health Companies Inc. | 72% | the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the study… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: source for their respective manufacturing and supplies. Failure of any of these contractors could affect our ability to have clinical trial material available… |
| IOBTQ | IOBTQ | 72% | Reciprocal relationship from IOBTQ graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual p… |
| IOBTQ | IOBTQ | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| LLY | Eli Lilly and Company | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual pro… |
| NVO | Novo Nordisk A/S | 72% | . We currently do not intend to sell these securities prior to maturity and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from NKTR graph: . We currently do not intend to sell these securities prior to maturity and it is more likely than not that we will no… |
| ODTX | ODTX | 72% | Reciprocal relationship from ODTX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from ODTX graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Fa… |
| ODTX | ODTX | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| PLRX | Pliant Therapeutics, Inc. | 72% | Reciprocal relationship from PLRX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PLRX g… |
| PSTV | Plus Therapeutics, Inc. | 72% | Reciprocal relationship from PSTV graph: iolabeled nanoliposome platform was developed by a multi-institutional consortium based in Texas at the Mays Cancer Center / UTHSCSA MD Anderson Cancer Center… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from SGMO g… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NKTR graph: em 1A. Risk Factors, including wi… |
| SNYNF | Sanofi | 72% | em 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, i… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the study… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from NKTR graph: the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all t… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NKTR-DEBT-11282 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2011-12-31. |
| NKTR-DEBT | Debt stack $143.4M | 90% | Market cache reports total debt of $143.4M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| NKTR-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 209 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AMGN | Amgen Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CANF | Can-Fite BioPharma Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 |